Surgery hip replacement

Hip replacement surgery is now routinely used to relieve pain and restore mobility in patients suffering from osteoarthritis. In this condition the surfaces of bone in contact with each other within the joint become worn and the layer of lubricating cartilage disappears. This makes movement of the joint both difficult and painful. By replacing the hip with an artificial joint patients stop experiencing pain and are once again able to move freely. 

Desirudin is a SC administered DTI approved for VTE prevention after hip replacement surgery but is not yet commercially available in the United States. Desirudin has an elimination half-life of 2 to 3 hours and is typically dosed every 12 hours. It is primarily eliminated through the kidneys, so dose reduction is needed in patients with renal impairment. The aPTT should be used to measure desirudin s anticoagulant activity.29,38,41... 

Desirudin (Iprivask) is approved for prevention of DVT in patients undergoing elective hip replacement surgery it is expected to be available for sale in the United States in late 2008. The recommended dose is 15 mg subcutaneously every 12 hours beginning 5 to 15 minutes prior to surgery and for up to 12 days thereafter. Daily aPTT monitoring is recommended. 

Hip replacement surgery The usual duration of administration is 5 to 10 days after surgery up to 14 days was well tolerated in controlled clinical trials. 

For hip replacement surgery, consider a dose of 40 mg once daily subcutaneously, given initially 9 to 15 hours prior to surgery. Continue prophylaxis for 3 weeks. 

Prophylaxis of deep vein thrombosis (DVT) For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism (PE) in patients undergoing the following hip fracture surgery, including extended prophylaxis hip replacement surgery or knee replacement surgery. 

DVT prophylaxis In patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery, the recommended dose is 2.5 mg subcutaneously once daily. After hemostasis has been established, give the initial dose 6 to 8 hours after surgery. The usual duration of administration is 5 to 9 days. Admixture incompatibilities Do not mix fondaparinux with other injections or infusions. 

Inhibition of abnormal calcification initials explorations of BPs as inhibitors of calcification showed promise, and early applications of etidronate included use in myositis ossificans, as well as in patients who had undergone total hip replacement surgery, in order to prevent subsequent heterotopic ossification and to improve mobility [10]. 

Treatment of actual symptoms of osteoporosis include pain medications and heat for vertebral compressions, simple casts for uncomplicated fractures, or hip replacement surgery for more complicated hip fractures. 

Murphy, P. Heal, J.M. Blumberg, N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion 1991, 31, 312-317. 

Hayes A, Murphy DB, McCarroll M. The efficacy of singledose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 1996 8(5) 357-60. 

Lassen MR, Bauer KA, Eriksson Bl, Turpie AG European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery a randomised double-bhnd comparison. Lancet 2002 359(9319) 1715-20. 

HPI AF is a 55-year-old woman who is scheduled to undergo left hip replacement surgery. While in the operating room and postanesthesia care unit (PACU), she has on thromboembolic deterrent (TED) stockings and sequential compression devices (SCDs). On postoperative day 1, the SCDs are discontinued, and she is started on enoxaparin for deep vein thrombosis (DVT) prophylaxis. On postoperative day 7, as AF is getting ready for discharge, she becomes acutely short of breath and develops a painful and swollen left leg. 

Fondaparinux is a selective inhibitor factor Xa possessing a selective inhibition of antithrombin III (ATIII), which potentiates the innate neutralization of factor Xa by ATIII. Nentralization of factor Xa interrupts the blood coagulation cascade and inhibits thrombin formation and thrombus development. It is indicated for prophylaxis of deep vein thrombosis (DVT) that may lead to pulmonary embolism in patients undergoing hip fracture surgery including extended prophylaxis, hip replacement surgery, or knee replacement surgery. When administered in conjunction with warfarin, fondaparinux is indicated for treatment of acute DVT and acute pulmonary embolism. 

Fitzpatrick R., E. Shortall, M. Sculpher, et al. 1998. Primary total hip replacement surgery A systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess 2 1-64. 

Joskowicz, L., et al., Computer Integrated Revision Total Hip Replacement Surgery Preliminary Repoit, Second Annual International Symposium on Medical Robotics and Computer Assisted Surgery, 1995, Baltimore. 

DiGioia, A. M., et al., HipNav Pre-operative Planning and Intra-operative Navigational Guidance for Acetabular Implant Placement in Total Hip Replacement Surgery, Computer Assisted Orthopedic Surgery, 1996. 

A 77-year-old woman undergoing hip replacement surgery received spinal anesthesia with bupivacaine 12 mg. On the first postoperative day she suddenly developed shock-like involuntary jerks, which were diagnosed as spinal myoclonus and confirmed by clinical and elec-trophysiological studies. She was given valproate and clonazepam, and the transient myoclonus disappeared after 4 days. 

Taylor RH, Joskowicz L, Williamson B, Gueziec A, Kalvin A, Kazanzides P, Van Vorhis R, Yao J, Kumar R, Bzostek A, Sahay A, Borner M, and Lahmer A, Computer-integrated revision total hip replacement surgery Concept and preliminary results. Medical Image Analysis, vol. 3 3, pp. 301-319,1999. 

The first metallic hip replacement surgery was conducted in 1940 by American surgeon Austin T. Moore. Hip replacement is regarded as the most successful orthopedic surgery, with more than 97 percent of patients reporting successful outcomes. 

---